Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.79 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.79 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | PDE4A | P27815 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TOP1 | P11387 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sorbitol SCHEMBL11519008 | 1.00 | LMNA (0.79) | LMNAL3MBTL1TDP1ALDH1A1KDM4E | |
| Mannitol SCHEMBL8671937 | 1.00 | LMNA (0.79) | LMNAL3MBTL1TDP1ALDH1A1KDM4E | |
| Galactitol SCHEMBL11516787 | 1.00 | LMNA (0.79) | LMNAL3MBTL1TDP1ALDH1A1KDM4E | |
| Mannitol SCHEMBL27259380 | 1.00 | LMNA (0.79) | LMNAL3MBTL1TDP1ALDH1A1KDM4E | |
| Mannitol SCHEMBL5565935 | 1.00 | LMNA (0.79) | LMNAL3MBTL1TDP1ALDH1A1KDM4E | |
| Sorbitol SCHEMBL9654601 | 1.00 | LMNA (0.79) | LMNAL3MBTL1TDP1ALDH1A1KDM4E | |
| Mannitol SCHEMBL28980943 | 1.00 | LMNA (0.79) | LMNAL3MBTL1TDP1ALDH1A1KDM4E | |
| Sorbitol SCHEMBL8145945 | 0.97 | LMNA (0.73) | LMNAL3MBTL1TDP1ALDH1A1KDM4E | |
| Mannitol SCHEMBL2785381 | 0.94 | LMNA (0.69) | LMNAL3MBTL1TDP1ALDH1A1KDM4E | |
| Mannitol SCHEMBL9580709 | 0.94 | LMNA (0.69) | LMNAL3MBTL1TDP1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 978 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240000678-A1 | COMPOSITIONS AND METHODS FOR STYLING HAIR | L'OREAL (FR) | 2024-01-04 | — | — | US | claimed |
| CN-114534702-A | Starch grafted and coated active coke loaded nano zero-valent iron composite material and preparation method thereof | 榆林学院 | 2022-05-27 | — | — | CN | claimed |
| CN-112263996-A | Starch grafted coal gangue coated nano zero-valent iron composite material and preparation method thereof | 榆林学院 | 2021-01-26 | — | — | CN | claimed |
| EP-2403818-B1 | CONVERSION OF SUGAR, SUGAR ALCOHOL, OR GLYCEROL TO VALUABLE CHEMICALS USING A PROMOTED ZIRCONIUM OXIDE SUPPORTED CATALYST | CLARIANT CORP (US) | 2020-07-15 | — | — | EP | claimed |
| CN-110755365-A | Hydrogel based on mesenchymal stem cell exosomes and preparation method of spray thereof | 江苏拓弘康恒医药有限公司 | 2020-02-07 | — | — | CN | claimed |
| CN-110591155-A | Composite super absorbent polymer containing coal gangue and starch and preparation method thereof | 榆林学院 | 2019-12-20 | — | — | CN | claimed |
| EP-2203181-B1 | AN ORALLY ADMINISTERABLE SOLID PHARMACEUTICAL COMPOSITION AND A PROCESS THEREOF | BIOCON LTD (IN) | 2018-02-14 | — | — | EP | claimed |
| US-9861585-B2 | Osmotic floating tablets | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2018-01-09 | — | — | US | claimed |
| US-9387178-B2 | Modified release tranexamic acid formulation | ACTAVIS, INC. (US) | 2016-07-12 | — | — | US | claimed |
| US-9241908-B2 | Orally administrable solid pharmaceutical composition and a process thereof | BIOCON LIMITED (IN) | 2016-01-26 | — | — | US | claimed |
| US-20030211154-A1 | Coating composition for facilitating controlled release | RANBAXY LABORATORIES LIMITED (IN) | 2003-11-13 | — | — | US | claimed |
| EP-1333816-A2 | MEDICINE BASED ON ANTI-HYPERGLYCAEMIC MICROCAPSULES WITH PROLONGED RELEASE AND METHOD FOR PREPARING SAME | FLAMEL TECHNOLOGIES (FR) | 2003-08-13 | — | — | EP | claimed |
| EP-1283701-A1 | A COATING COMPOSITION FOR FACILITATING CONTROLLED RELEASE | Ranbaxy Laboratories Limited (IN) | 2003-02-19 | — | — | EP | claimed |
| US-20030017209-A1 | Breath protection microcapsules | WARNER-LAMBERT COMPANY | 2003-01-23 | — | — | US | claimed |
| WO-2002094285-A1 | SINGLE-DAILY-DOSE ANTIDIABETIC ORAL PHARMACEUTICAL FORM COMPRISING A BIGUANIDE AND AT LEAST ANOTHER ACTIVE PRINCIPLE | FLAMEL TECHNOLOGIES (FR) | 2002-11-28 | — | — | WO | claimed |
| US-6423329-B1 | SANITIZING AGENT FOR SKIN, HUMECTANTS AND DETACKIFIERS | THE PROCTER & GAMBLE COMPANY | 2002-07-23 | — | — | US | claimed |
| WO-2002039984-A2 | MEDICINE BASED ON ANTI-HYPERGLYCAEMIC MICROCAPSULES WITH PROLONGED RELEASE | FLAMEL TECHNOLOGIES (FR) | 2002-05-23 | — | — | WO | claimed |
| WO-2001087269-A1 | A COATING COMPOSITION FOR FACILITATING CONTROLLED RELEASE | RANBAXY LABORATORIES LIMITED (IN) | 2001-11-22 | — | — | WO | claimed |
| EP-0143857-B1 | THERAPEUTIC CORONARY COMPOSITION IN THE FORM OF SOFT GELATINE CAPSULES | SIEGFRIED AKTIENGESELLSCHAFT (CH) | 1988-04-06 | — | — | EP | claimed |
| EP-0143857-A1 | Therapeutic coronary composition in the form of soft gelatine capsules | SIEGFRIED AKTIENGESELLSCHAFT (CH) | 1985-06-12 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030017209-A1 | Breath protection microcapsules | MLYCD, SCD5, FBP1 | LMNA 3674/4885L3MBTL1 686/4885TDP1 4505/4885 |
| US-20240000678-A1 | COMPOSITIONS AND METHODS FOR STYLING HAIR | PIK3C3, DPM1, SUCLG1 | LMNA 1496/4885L3MBTL1 4754/4885TDP1 1035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.